Moderna to Join Nasdaq 100 Index; High-Earnings Accounts Predict 70% Price Increase

Huo Xing Finance reports: On October 9, Moderna will be officially added to the Nasdaq-100 Index at 21:30 Beijing time on October 9, prior to the opening of U.S. markets, replacing Warner Bros. Discovery. This adjustment was announced on October 1. From the close of U.S. markets on October 1, prior to the announcement, to the latest close on October 8, Moderna’s stock price rose from $188.94 to $197, representing a cumulative increase of approximately 4.27%. Moderna is a U.S. biotechnology company specializing in mRNA-based vaccine and drug development, with research spanning infectious diseases, cancer, and rare diseases. In addition to its vaccine business, the company’s personalized mRNA cancer therapy developed in collaboration with Merck reported positive Phase III trial results in August, achieving its primary endpoint of recurrence-free survival in melanoma adjuvant treatment—a key catalyst for the stock price. Recently, a suspected case of pneumonic plague in Russia has drawn attention to vaccine stocks; Moderna’s shares rose approximately 6.95% on October 5. However, according to the latest publicly available information, the pathogen has not yet been confirmed by the WHO, and Russian authorities report no confirmed plague cases among contacts; the European Centre for Disease Prevention and Control also states there is no evidence of sustained human-to-human transmission. According to TradingBeats monitoring, the MRNA perpetual contract is trading at $196.45, up approximately 0.56% over 24 hours; open interest stands at approximately 15,600 contracts, with a notional value of about $3.059 million; trading volume over 24 hours reached approximately 43,500 contracts, with a turnover of about $8.521 million. The two largest long positions together hold approximately $448,500 in long exposure, with unrealized profits of approximately $61,500: - Largest long: Approximately $242,500 in long exposure. Holding 1,233.05 contracts with 3x leverage at an average price of $175.78, with an unrealized profit of approximately $25,800, a return of about 35.7%, and a liquidation price of $124.15 (0x9a37…). - Second-largest long: Approximately $205,900 in long exposure. Holding 1,046.98 contracts with 10x leverage at an average price of $162.58, with an unrealized profit of approximately $35,700, a return of about 209.8%, and a liquidation price of $154.69 (0x599d…). The second-largest long has set a market-order take-profit trigger at $350, covering all current positions—approximately 77.9% above the current price.